Free shipping on all orders over $ 500

Mosunetuzumab

Cat. No. M24845
Mosunetuzumab Structure
Synonym:

BTCT-4465A

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mosunetuzumab (BTCT-4465A) is a humanized, immunoglobulin G1-based bispecific antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).

Chemical Information
CAS Number 1905409-39-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] No authors listed. Mosunetuzumab

[2] Connie Kang. Drugs. Mosunetuzumab: First Approval

[3] Lihua E Budde, et al. Lancet Oncol. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

[4] Christian Buske. Lancet Oncol. Mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma

[5] Lihua E Budde, et al. J Clin Oncol. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Related CD20 Products
Epcoritamab

Epcoritamab is a novel bispecific IgG1k/λ antibody targeting CD3 and CD20 that activates T cells and directs them to kill malignant CD20+ B cells.Epcoritamab has antitumor activity and may be used in studies related to RR diffuse large B-cell lymphoma (DLBCL).

Zebituzumab

Zebituzumab (zebituzumab) is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody that can be used in studies related to CD20-positive diffuse large B-cell lymphoma.

Veltuzumab

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).

Divozilimab

Divozilimab (BCD-132) is a humanized anti-CD20 IgG1ҡ monoclonal antibody for use in studies related to multiple sclerosis.

Zuberitamab

Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.

  Catalog
Abmole Inhibitor Catalog




Keywords: Mosunetuzumab, BTCT-4465A supplier, CD20, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.